8521 Background: The central nervous system (CNS), particularly after progression on third-generation EGFR TKIs, represents a common yet challenging scenario. While recent trials establish amivantamab-lazertinib for EGFR-mutant NSCLC, their real-world applicability is limited by patient complexity and access barriers, highlighting an urgent need for flexible, real-world solutions. Methods: To evaluate the intracranial efficacy of amivantamab, used as monotherapy or in combination, we conducted a